Mary-Louise Hoffman
SAP AG is exploring clinical applications for its HANA in-memory database platform in a bid to boost revenue from the healthcare market, The Wall Street Journal reported Wednesday.
Ursula Quass writes SAP sees new business opportunities for the software in the pharmaceutical research arena and in the fields of human genomics and protein analysis.
“We’ve seen interest from (large pharma companies) after holding first discussions with them,” Franz Faerber, SAP manager, told the newspaper.
Quass writes that HANA is designed to analyze huge volumes of data in real time and SAP believes the technology could help researchers determine the most effective dose of experimental drugs.
